Top Page
Moleculin Biotech
(NASDAQ:MBRX)
Moleculin Biotech (MBRX) vs. SPDR S&P 500 ETF (SPY)
Moleculin Biotech Business Overview & Revenue Model
Moleculin Biotech Earnings Call Summary
Moleculin Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -81.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -40.75M | -26.52M | -29.50M | -30.51M | -22.80M | -19.54M |
| Net Income | -41.36M | -21.76M | -29.77M | -29.02M | -15.89M | -17.36M |
Balance Sheet | ||||||
| Total Assets | 20.35M | 16.93M | 38.22M | 57.42M | 84.09M | 29.16M |
| Cash, Cash Equivalents and Short-Term Investments | 6.70M | 4.28M | 23.55M | 43.15M | 70.90M | 15.17M |
| Total Debt | 390.00K | 478.00K | 574.00K | 451.00K | 159.00K | 277.00K |
| Total Liabilities | 47.27M | 10.95M | 12.14M | 5.23M | 5.10M | 11.27M |
| Stockholders Equity | -26.92M | 5.98M | 26.07M | 52.19M | 78.99M | 17.89M |
Cash Flow | ||||||
| Free Cash Flow | -22.45M | -23.88M | -24.23M | -27.71M | -18.97M | -18.15M |
| Operating Cash Flow | -22.45M | -23.86M | -24.10M | -27.64M | -18.95M | -17.77M |
| Investing Cash Flow | 0.00 | -13.00K | -124.00K | -67.00K | -19.00K | -374.00K |
| Financing Cash Flow | 19.80M | 4.63M | 4.65M | -23.00K | 74.72M | 22.55M |
Moleculin Biotech Technical Analysis
Moleculin Biotech Risk Analysis
Moleculin Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $60.72M | -1.82 | -54.50% | ― | 185.71% | 79.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $105.80M | -0.62 | -328.45% | ― | -10.36% | 42.36% | |
45 Neutral | $12.47M | -0.07 | ― | ― | ― | 79.31% | |
42 Neutral | $8.97M | ― | -196.60% | ― | ― | ― |
Moleculin Biotech Corporate Events
On January 13, 2026, Moleculin Biotech reported that an independent expert’s review of data from 90 subjects treated with its lead drug candidate Annamycin across five clinical trials in AML and STS found no evidence of cardiotoxicity, even though most participants received doses exceeding the U.S. FDA’s recommended lifetime exposure for conventional anthracyclines. The assessment, based on serial ECGs, echocardiography with global longitudinal strain analysis and cardiac biomarkers, reinforces Moleculin’s positioning of Annamycin as a potential non-cardiotoxic, next-generation anthracycline in a cancer treatment landscape where existing anthracyclines are widely used but linked to long-term heart damage, and it supports the company’s ongoing development programs and its argument for a significant market opportunity if the safety and efficacy profile is confirmed in further studies.
The most recent analyst rating on (MBRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On January 12, 2026, Moleculin Biotech outlined an accelerated development and clinical outlook centered on its lead drug Annamycin and its STAT3 inhibitor WP1066, highlighting a pivotal global Phase 3 AML trial, new indications, and multiple externally funded studies. The company reported that its MIRACLE Phase 3 trial of Annamycin in combination with cytarabine for relapsed or refractory AML has expanded to nine countries with more than 46 sites selected, remains on track to treat the 45th subject and undergo its first unblinding in the first quarter of 2026, and is expected to reach 90 subjects and a second unblinding by the third quarter of 2026, with Part B initiation in the second half of 2026 and primary efficacy data targeted for 2028. Management emphasized Annamycin’s potential to be the first non-cardiotoxic anthracycline, citing an upcoming Q1 2026 review of cardiotoxicity data and positioning the candidate for a large commercial opportunity given the widespread use and cardiac risks of current anthracyclines. Moleculin also detailed plans for an Atlantic Health–funded investigator-initiated trial of Annamycin in third-line pancreatic cancer expected to start in 2026 and future expansion into third-line and pediatric AML, while projecting a rolling new drug application submission for MIRACLE in 2028. For WP1066, the company highlighted ongoing and planned investigator-initiated programs, including an externally funded Phase 2 trial in glioblastoma at Northwestern University and pediatric brain tumor work at Emory University, with additional preclinical efforts on an intravenous formulation aimed at advancing the drug against brain cancers and potentially overcoming the long-standing challenge of directly targeting STAT3.
The most recent analyst rating on (MBRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On May 23, 2025, Moleculin Biotech, Inc. was notified by Nasdaq that it was not in compliance with the exchange’s Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and that it also failed to meet alternative standards related to market value of listed securities or net income from continuing operations. After receiving a delisting determination on November 20, 2025, and requesting a hearing, the company was informed on January 6, 2026, that it had regained compliance with all applicable Nasdaq continued listing requirements, leading to the cancellation of the scheduled hearing and removing the immediate risk of its shares being delisted from the exchange.
The most recent analyst rating on (MBRX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On December 21, 2025, Moleculin Biotech, Inc. amended its Series E, F and G warrants, reducing the exercise price to $3.90 per share, removing certain anti-dilution and price-adjustment provisions in the Series E and F warrants, and revising the Black Scholes Value definition, changes that allowed reclassification of affected warrants from liabilities to equity. The company has been working to regain compliance with Nasdaq’s minimum stockholders’ equity requirement after a May 23, 2025 deficiency notice and a November 20, 2025 delisting determination, and by December 2025 it completed a $6.8 million warrant inducement financing, raised about $1.1 million through its at-the-market offering, and executed the warrant amendments, actions that moved it from a $26.9 million stockholders’ deficit as of September 30, 2025 to more than $10 million in stockholders’ equity ahead of a scheduled Nasdaq hearing on January 20, 2026.
The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On December 17, 2025, Moleculin Biotech announced promising results from a physician-sponsored Phase 1 clinical trial of WP1066, conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta. The trial, led by pediatric oncologist Dr. Tobey MacDonald, demonstrated WP1066’s safety profile and effectiveness in inducing anti-tumor immune responses for children with recurrent malignant brain tumors, such as high-grade glioma and diffuse intrinsic pontine glioma, conditions with limited existing treatments. These findings, published in the Journal of Clinical Investigation Insight, pave the way for a Phase 2 trial, potentially offering a novel treatment approach for these challenging pediatric cancers.
The most recent analyst rating on (MBRX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Moleculin Biotech, Inc. received a deficiency letter from Nasdaq on June 27, 2025, due to its stock price falling below the $1.00 minimum requirement. However, by December 15, 2025, the company regained compliance as its stock price met the required threshold for 10 consecutive business days, resolving the issue.
The most recent analyst rating on (MBRX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On December 9, 2025, Moleculin Biotech, Inc. entered into inducement offer agreements with holders of existing warrants, allowing them to exercise their warrants at adjusted prices. This agreement is expected to generate up to $6.8 million in gross proceeds for the company, enhancing its financial position and potentially impacting its market operations by increasing the number of shares available for trading.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On December 9, 2025, Moleculin Biotech announced an update on its pivotal Phase 2B/3 MIRACLE study of Annamycin for treating relapsed or refractory acute myeloid leukemia (AML). The enrollment has increased to 78% of the target for the first interim unblinding, with completion expected in the first quarter of 2026. This progress supports the potential of Annamycin to address a significant gap in AML treatment, with the trial expanding across seven countries. The company aims to complete Part A of the trial with 90 subjects by mid-2026, as they continue to recruit and analyze data to determine the best dosage for further trials.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On December 8, 2025, Moleculin Biotech announced a research and material transfer agreement with CIC biomaGUNE to evaluate Annamycin for treating glioblastoma multiforme, a form of brain cancer. This collaboration aims to explore Annamycin’s potential in overcoming drug delivery challenges in central nervous system tumors, highlighting the company’s commitment to innovative cancer therapies.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On November 26, 2025, Moleculin Biotech announced a 1-for-25 reverse stock split of its common stock, effective December 1, 2025. This move, approved by stockholders on August 18, 2025, reduces the number of outstanding shares from approximately 51.6 million to 2.07 million, while maintaining the authorized shares at 500 million. The reverse split aims to adjust the stock price and shares outstanding, impacting the exercise prices and share numbers for stock options and warrants, with no fractional shares issued.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On November 24, 2025, Moleculin Biotech, Inc. utilized a corporate presentation on its website, which was also included as Exhibit 99.1 in a Current Report on Form 8-K. The information provided in the report is not intended to be filed under the Securities Exchange Act of 1934 or the Securities Act of 1933 unless specifically stated otherwise.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On November 20, 2025, Moleculin Biotech received a delist determination letter from Nasdaq, indicating the company had not regained compliance with the minimum stockholders’ equity requirement of $2.5 million. The company plans to appeal this determination to a Nasdaq hearing panel to prevent its securities from being delisted on December 2, 2025, and its common stock will continue to trade under the symbol ‘MBRX’ pending the appeal outcome.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On November 13, 2025, Moleculin Biotech announced that 60% of the target subjects have consented to participate in its pivotal Phase 2B/3 MIRACLE study of Annamycin for treating relapsed or refractory acute myeloid leukemia (AML). The company aims to complete treatment of the first 45 subjects by the first quarter of 2026, with initial unblinding of data expected thereafter. Despite some recruitment challenges in Europe, the study is progressing well, and Moleculin is optimistic about Annamycin’s potential to address a significant gap in AML treatment.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On November 12, 2025, Moleculin Biotech announced a research and material transfer agreement with the University of North Carolina at Chapel Hill to evaluate Annamycin for pancreatic cancer treatment. This collaboration aims to enhance the delivery of Annamycin in preclinical studies, potentially expanding its clinical applications and strengthening Moleculin’s oncology development pipeline.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On October 30, 2025, Moleculin Biotech, Inc. utilized a corporate presentation, which was posted on their website, as part of their communication strategy. This presentation, detailed in Exhibit 99.1, was shared for informational purposes and is not intended to be filed under the Securities Exchange Act of 1934 or the Securities Act of 1933.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On October 29, 2025, Moleculin Biotech announced the granting of an Australian patent for its Annamycin drug, a significant step in expanding its global intellectual property portfolio. This patent, which extends until June 2040, covers preliposomal Annamycin lyophilizates with improved stability and purity, reinforcing the company’s competitive position in oncology and its commitment to advancing Annamycin as a transformative treatment for hard-to-treat cancers.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On October 23, 2025, Moleculin Biotech announced a collaboration with Atlantic Health System to initiate a Phase 1B/2 study of Annamycin for third-line treatment of advanced pancreatic cancer. This study aims to address the high mortality rate of pancreatic cancer by leveraging Annamycin’s potential to target critical factors in the disease. The partnership highlights Moleculin’s strategy to expand Annamycin’s therapeutic applications and strengthen its position in the oncology market, with potential implications for improving treatment options for pancreatic cancer patients.
The most recent analyst rating on (MBRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
On October 16, 2025, Moleculin Biotech held a Special Meeting of Stockholders where several proposals were voted on. The stockholders approved the issuance of up to 64,864,864 shares of common stock upon the exercise of certain warrants, but did not approve the proposal to change the company’s name to Moleculin Inc. Additionally, they approved an adjournment to solicit more proxies if needed for the Nasdaq Proposal or the Name Change Proposal.
The most recent analyst rating on (MBRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.